Consequences of reducing hypoglycemiainducing glucose-lowering medication (medication that lowers glucose (sugar) levels in the blood and can cause low blood sugar) in people with type 2 diabetes of 70 years or older

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
02/03/2023		[X] Protocol		
Registration date	Overall study status Ongoing Condition category	Statistical analysis plan		
09/03/2023		Results		
Last Edited		Individual participant data		
29/07/2024	Nutritional, Metabolic, Endocrine	Record updated in last year		

Plain English summary of protocol

Background and study aims

Older people with type 2 diabetes have a higher risk of health problems like low blood sugar, disability, and death from diabetes medications. In the Netherlands, a study found that many hospital admissions of older people were caused by low blood sugar from insulin or sulfonyl urea drugs. Low blood sugar also increases the risk of falls, fractures, and dementia. Frailty can make diabetes worse and increase the risk of low blood sugar even more. Guidelines suggest being less strict about controlling blood sugar in older people with diabetes, but many doctors still give too much medication. They may not know how to reduce medication safely or worry about the risks of high blood sugar. To make sure it's safe to reduce medication, more research is needed. This study aims to see if reducing medication for older people with diabetes is safe and improves quality of life. It will also look at how to do this in practice and if it saves money.

Who can participate?

People with type 2 diabetes over 70 years of age who are using insulin or sulfonyl urea derivates and have Hba1c levels below the suggested thresholds of the 2018 Diabetes guideline of the Dutch Society of General Practitioners.

What does the study involve?

Reducing medication until acceptable levels of Hba1c have been reached. The reduction of the medication and the selection of the threshold is defined in a shared decision making procedure between patient and health care professional. Patients who indicate willingness after a written invitation will be invited to fill in 6-monthly questionnaires during a follow up period of five years (five questionnaires) and might be invited for an interview.

What are the possible benefits and risks of participating? Possible benefits: reduction of hypoglycemic episodes with negative consequences Possible risks: increase of hyperglycemic episodes with negative consequences

When is the study starting and how long is it expected to run for? January 2021 to July 2026

Who is funding the study?

The study is funded by ZonMW, The Netherlands organisation for health research and development.

Who is the main contact? Prof.dr. P.J.M. Elders, p.elders@amsterdamumc.nl

Contact information

Type(s)

Public

Contact name

Dr Marieke Blom

ORCID ID

https://orcid.org/0000-0002-8088-1105

Contact details

Department of General Practice Amsterdam UMC, location AMC Meibergdreef 9 Amsterdam Netherlands 1100 DD +31 610305382 m.t.blom@amsterdamumc.nl

Type(s)

Scientific

Contact name

Prof Petra Elders

ORCID ID

https://orcid.org/0000-0002-5907-7219

Contact details

Department of General Practice Amsterdam UMC, location AMC Meibergdreef 9 Amsterdam Netherlands 1100 DD +31 610305382 p.elders@amsterdamumc.nl

Type(s)

Principal investigator

Contact name

Prof Petra Elders

Contact details

Department of General Practice Amsterdam UMC, location AMC Meibergdreef 9 Amsterdam Netherlands 1100 DD +31 610305382 p.elders@amsterdamumc.nl

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Zonmw file number 848018102

Study information

Scientific Title

Consequences of reducing hypoglycemia-inducing glucose-lowering medication in people with type two diabetes: an open cluster controlled intervention study comparing the implementation of a deprescribing program in primary care practises versus usual care

Acronym

OMED2

Study objectives

Reducing hypoglycemia inducing glucose lowering medication in people of 70 years or older in order to meet the criteria of the 2018 guideline of the Dutch Society of General Practice does not lead to increased registered medical problems by the GP that are are -according to a delphi procedure with GP's - related to hyperglycemia or hyperglycemia, reduced quality of life or increased cost.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The ethics committee of Amsterdam UMC, location VU deemed that the study did not fall under the reserach with human subjects act (correspondence number 2021.0231) after wich the Directory Board of Amsterdam UMC, location VU approved of the study.

Study design

Open cluster randomized study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Complications of type 2 diabetes

Interventions

The intervention consists of an implementation program aimed at reducing glucose-lowering medications in people of 70 years of age that have too low Hba1c according to the 2018 guideline of the Dutch Society of General Practitioners and are treated with potentially hypoglycaemia-inducing glucose-lowering medication. The study compares the intervention to usual care.

The implementation program consists of digital training sessions, a digital algorithm to select the potential patients for the program, supporting practice visits by specially trained medical students or research assistants and an expert panel consisting of a GP expert in Diabetes, a pharmacist, a diabetologist and a geriatrician.

The control practices receive an implementation program in which the prescription of SGLT2 inhibitors or GLP1 agonist is stimulated in patients younger than 70 years with manifest diabetes complications.

Before practices receive the training program for the study which depends on the intervention allocation, participating practices will be randomly allocated to the intervention, or control condition. Randomisation will be performed by a researcher blinded to characteristics of the practices using a digital tool. Practices starting the monthly training course are stratified by practice size (two strata), to ensure equally sized groups. Patients will be allocated to either one of the treatment conditions, based on the practice where they are listed. Blinding of patients, GPs and practice nurses to treatment allocation is not possible due to the nature of the intervention.

Intervention Type

Mixed

Primary outcome(s)

Two year follow up count of all ICPC coded reasons of encounter registered in the routine care electronical register of the GP practice that are potentially related to hypoglycemia selected in a Delphi procedure by three GP's.

Key secondary outcome(s))

- 1. Two year follow up count of all ICPC coded reasons of encounter selected in a Delphi procedure by three GP's registered in the routine
- care electronic register of the GP practice that are potentially related to hyperglycemia.
- 2. Two year follow up count of all ICPC coded reasons of encounter selected in a Delphi procedure by three GP's registered in the routine care electronic register of the GP practice that are potentially related to either hyperalyce.
- care electronic register of the GP practice that are potentially related to either hyperglycemia or hypoglycemia.
- 3. Quality of life, measured every six months using the EQ5D-5L and EQ5D-VAS as indicated by patients agreeing to fill in 6-monthly questionnaires.
- 4. Blood pressure measurements and laboratory measurements registered in the routine care electronic digital file of the GP: Hba1c, fasting plasma glucose measurements.
- 5. Number of medication prescriptions registered in the EMR
- 6. Hospital admissions, visits to emergency departments (hospital or primary care) and nursing home admissions as indicated by patients agreeing to fill in 6-monthly questionnaires.
- 7. Health care and patient cost including medical prescription data will be analyzed from the societal perspective based on 6 monthly patient questionnaires.
- 8. Cognitive evaluation using the Minicog questionnaire if deemed necessary by the health care professionals and registered in the medical file.
- 9. Process analysis: for the purpose of studying the implementation, we shall study an extraction of the EMR of the patients who were selected for DDP in the intervention study. As part of the analysis all free text in the GP file will be extracted and after erasing all potential identifying information, will be studied as well. Using the administrative labels regarding inclusion and participation in the DDP, we will be able to deduce the aspects that caused enrollment or exclusion in the DDP intervention and how it was performed and which medical interventions (medication changes, lab measurements) were done. We shall also organize interviews with GP's, PN's. A random number of 20 study participants will be approached for an interview during the study to study whether we might improve the program (training, materials) further.

Completion date

01/07/2026

Eligibility

Key inclusion criteria

- 1. Age 70 years or older
- 2. Having type 2 diabetes
- 3. Using insulin or sulfonyl urea derivative drugs
- 4. Recent Hba1c below 54 mmol/mol or if deemed fragile by the GP practice below 58mmol/mol

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Lower age limit

Sex

All

Key exclusion criteria

Previously having indicated to be not willing to participate in studies using routine care electronic data

Date of first enrolment

13/03/2023

Date of final enrolment

13/03/2024

Locations

Countries of recruitment

Netherlands

Study participating centre

Amsterdam UMC, Department of General Practice

Amsterdam UMC, location AMC Meibergdreef 9 Amsterdam Netherlands 1100 DD

Study participating centre

Department of Public Health and Primary Care, Universy Medical Center Leiden

Hippocratespad 21 Leiden Netherlands 2333ZD

Sponsor information

Organisation

Amsterdam University Medical Centers

ROR

https://ror.org/05grdyy37

Funder(s)

Funder type

Research organisation

Funder Name

ZonMw

Alternative Name(s)

Netherlands Organisation for Health Research and Development

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

Netherlands

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at later date

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol article</u>		25/07/2024	29/07/2024	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes